Elaine R Mardis from the Nationwide Children’s Hospital & Ohio State University College of Medicine, OH, US, and AACR President-Elect (2018–2019), talks to us about her upcoming role and how AACR aims to meet unmet needs in cancer research and personalized medicine in the future.
1. What are the main aims of the American Association for Cancer Research (AACR)? (0:08)
2. What do you anticipate to be the major challenges of your role as president of the AACR? (0:31)
3. What have been the most exciting developments in the genomic characterization of cancer in the past year? (1:35)
4. What are the major unmet needs in personalized cancer medicine? (2:19)
5. What do you expect to be the key themes of the AACR annual meeting? (3:24)Speaker disclosures: Elaine R Mardis has nothing to disclose in relation to this video interview.
Filmed at the American Association for Cancer Research (AACR) Annual Meeting 2018, Chicago, IL, US, April 14–18, 2018.
Share this Video
Related Videos In Haematological Malignancies
Andreas Hochhaus, ASH 2020 – The ASCEMBL Study and Asciminib in CML
touchONCOLOGY meets with Prof. Andreas Hochhaus to discuss the clinical development of asciminib and its potential as a therapy for chronic myeloid leukaemia. The abstract ‘Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic […]
Othman Al-Sawaf, ASH 2020 – Venetoclax-obinutuzumab and the CLL14 Trial
Dr Othman Al-Sawaf joins touchONCOLOGY to discuss the CLL14 trial and the impact of venetoclax-obinutuzumab treatment on clonal growth and the potential of its use in chronic lymphocytic leukaemia. The abstract ‘Clonal Dynamics after Venetoclax-Obinutuzumab Therapy: Novel Insights from the Randomized, Phase 3 CLL14 Trial’ (Abstract number 127) was presented at the 62nd American Society […]
Shaji Kumar, ASH 2020 – Highlights from ASH 2020
It was a pleasure to speak with our Editor-in-Chief, Shaji Kumar (Mayo Clinic, Rochester, MN, USA) to discuss the use of MEDI2228 (Clinical Trial Identifier: NCT03489525) and anti-BCMA CAR-T cells (Clinical Trial Identifier: NCT03915184) in the treatment of patients with relapsed/refractory multiple myeloma and to find out his personal highlights from this year’s congress. The […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!